Status:
COMPLETED
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Lead Sponsor:
Pfizer
Conditions:
Complicated Intra-abdominal Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
Eligibility Criteria
Inclusion
- complicated intra-abdominal infections
Exclusion
- infections limited to hollow viscus
- ischemic bowel disease without perforation
- acute suppurative cholangitis
- acute necrotizing pancreatitis
- pts to undergo stated abdominal repair, open abdomen technique or marsupialization
- Apache II \>25
Key Trial Info
Start Date :
March 31 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2009
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00752219
Start Date
March 31 2009
End Date
December 31 2009
Last Update
July 3 2018
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90033
2
Cedars-Sinai Medical Center Dept of Surgery
Los Angeles, California, United States
3
Michael S. Somero Research Division
Palm Springs, California, United States
4
Henry Ford Health System
Detroit, Michigan, United States